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Background: The etiology of osteonecrosis of femoral head (ONFH) has not been fully elucidated. Increased
intravascular coagulation and/or hypofibrinolysis have been proposed as pathogenic mechanisms. Previous reports
demonstrated significant association between incidence of ONFH and polymorphisms of genes related with
thrombophilia especially in Caucasian subjects. The aim of our study was to evaluate the relationship between
genetic mutations leading to coagulation disorders and ONFH in Polish patients.
Methods: We have investigated the frequencies of four markers among 68 unrelated individuals with clinically and
radiographically documented ONFH and among 100 healthy unrelated blood donors in Eastern part of Poland. The
three genes were involved in thrombophilia: factor V Leiden (G1691A), prothrombin (G20210A),
Methylenetetrahydrofolate Reductase (MTHFR C677T) and one in hypofibrinolysis: Tissue Plasminogen Activator
(PLAT TPA25 I/D). The samples were genotyped with polymerase chain reaction followed by restriction enzyme
analysis for the restriction fragment length polymorphisms. The allele and genotype frequencies were analyzed in
the relation to ONFH etiology (idiopathic and secondary), gender, age (patients younger or older than 50 years) and
the number of affected joints (unilateral or bilateral ONFH).
Results: No significant difference in allele frequencies between patients and control groups were observed in
genes involved in thrombophilia. We have found a statistically significant increased frequency of D allele of PLAT
TPA 25 I/D polymorphism between the entire group of patients with ONFH and controls (p=0,026, OR=1,54, CI
0,99-2,4). D allele frequency was also significantly increased in patients with primary ONFH (p=0,009, OR=1,81 CI 1,
1-3,01), in males (p= 0,013; OR 1,74; 95% CIs 1,08-2,78), patients older than 50 years (p= 0,018, OR= 2,04; 95% CIs
1,09-3,82) and in cases with bilateral ONFH (p= 0,01; OR= 1,92; 95% CIs 1,13-3,27) (Table 9). The differences in DD
homozygous genotype frequency were statistically significant for patients with idiopathic ONFH compared with
control group (p=0,023, OR=2,75, CI 0,99-7,9) and in cases of bilateral ONFH (p=0,034; OR 3,12; 95% CIs 1,06-9,18)
(Table 10). The frequencies of ID heterozygous genotype were statistically significantly higher in entire group of
patients with ONFH (p=0,004 OR 2,71; 95% CIs 1,32-5,57), idiopathic ONFH (p= 0,01; OR 2,91; 95% CIs 1,24-6,87),
males (p=0,0007; OR 3,75; 95% CIs 1,67-8,42), patients older than 50 years (p=0,001; OR 6,89; 95% CIs 1,87-25,84)
and in cases with bilateral ONFH (p=0,009; OR 3,19; 95% CIs 1,26-8,03).
Conclusion: The results suggest that inherited hypofibrinolysis is a risk factor of idiopathic ONFH in Polish
population.
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Table 1 Panel of markers included in the study
Gene Polymorphism Type References
Factor V Leiden G1691A RFLP Zoller et al. [12]
Prothrombin G20210A RFLP Poort et al. [13]
MTHFR C677T RFLP Friedman et al. [14]
PLAT TPA 25 I/D Ins.Alu Tishkoff et al. [15]
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Osteonecrosis (ON) or avascular necrosis (AVN) is a
clinical entity characterized by death of bone cellular
components due to interruption of blood supply [1]. The
actual prevalence of ONFH is unknown. The estimated 10
000 to 20 000 new cases of ONFH are diagnosed every
year in the United States [2]. ONFH occurs mainly in
young people. The evolution of the disease leads to fracture
of subchondral bone, collapse of the femoral head with
subsequent degenerative changes of hip joint [3]. ONFH
has traditionally been classified as idiopathic or secondary,
depending on the absence or presence of known causes
[1]. The most common risk factors of secondary ONFH
include: the use of corticosteroids, alcoholism, hyperlipid-
emia, lipid storage diseases, hyperbaric exposure, preg-
nancy, SLE, solid organ transplantations and chemotherapy.
The etiology and pathophysiology of ONFH have not been
fully elucidated. An Increased tendency of intravascular
coagulation has been proposed as pathogenic mechanism
of ONFH in adults at the beginning of 90s [4]. Both
thrombophilia (increased tendency to form thrombi) or/
and hypofibrinolysis (reduced ability to lyse thrombi)
may be the causes of ONFH in adults [5-7]. The same
thrombophilia/hypofibrinolysis pathomechanism has been
reported in ONFH in children (Legg-Calvé-Perthes
disease) [8,9].
The aim of this study was to evaluate the relationship
between genetic mutations leading to coagulation disorders
and ONFH in Polish patients.
Methods
Patients
A group of 68 unrelated adult individuals were involved
in this study. All the patients were Caucasians of Polish
origin coming from Eastern part of Poland. Patients
were admitted to the Department of Orthopaedics and
Traumatology for operative treatment of ONFH. ONFH
was diagnosed with clinical examination and radiographic
analysis. Patients without characteristic risk factors related
with ON were classified as idiopathic ONFH (n=45). The
cause of ONFH was established in 23 patients: the use of
corticosteroids (n=11), chemotherapy (n=7), alcoholism
(n=4), renal transplantation (n=1). These patients were
classified as secondary ONFH. Patients with idiopathic
and secondary ONFH did not differ in the relation of
average age and gender distribution. Ficat and Arlet
classification [10] was used for radiographic evaluation.
AP and axial view x-rays of both hips were taken in all of
the patients. MRI was performed to confirm the diagnosis
of ONFH in patients without x-ray changes. ONFH was
present in one hip in 29 patients and in both hips in 39
patients. Stage I according to Ficat and Arlet was seen in
11 hips, stage II in 19, III in 24 and IV degree in 53 hips.
Healthy control subjects (n=100) without any clinicalsigns and family history of ONFH were recruited among
blood donors and hospital staff. All the participants in the
control group also came from Eastern part of Poland.
Control group consisted of 20 women and 80 men with
average age of 36,6 (range from 20 to 55) years.
A written informed consent for genetic studies was
obtained from all the patients and subjects from the
control group. The study protocol was evaluated and
approved by the Ethics Committee at the Medical
University in Lublin.
Genetic testing
Genomic DNA was isolated from peripheral blood
leukocytes using the method described by Madisen et al.
[11] with minor modifications. The samples were geno-
typed using the polymerase chain reaction under condi-
tions previously described by authors [12-15] listed in
Table 1.
Statistical analysis
All the calculations were performed using SPSS for
Windows 17.0. Normally distributed data are presented as
means ± SD. Genotype distribution and allele frequencies
were compared between groups using x2 test and Fisher’s
exact test, respectively. Odds ratios (ORs) and 95% confi-
dence intervals (CIs) were calculated using relevant 2×2
contingency tables.
Results
We genotyped the polymorphisms of four genes related
to coagulation abnormalities in 68 patients with ONFH
and 100 healthy controls. Clinical characteristics of the
study group are summarized in Table 2. There were no
significant differences between the groups with respect
to age and gender ratio, the number of affected joints and
risk factors. We have found high incidence of smokers in
idiopathic ONFH group. We could not reveal that smoking
is a risk factor of ONFH because of lack of data on smoking
in the control group. Allele and genotype frequencies of
ONFH patients are presented in Tables 3 and 4. The
genotype frequencies of the four polymorphisms analyzed
were in Hardy Weinberg equilibrium. We analyzed the
allele and genotype frequencies in the relation to ONFH
etiology (idiopathic and secondary) (Tables 3 and 4), gender
(Tables 5 and 6), age (patients younger or older than 50
Table 2 Characteristics of ONFH study group
Osteonecrosis N=68 Idiopathic osteonecrosis n=45 Secondary osteonecrosis n=23
Gender (men/women) 56/12 (82,35%/17,65%) 38/7 (84,44%/15,56%) 18/5 (78,26%/21,74%)
Age (years) 44,98 (15-77) 44,42 (15-77) 46,08 (20-74)
Bilateral ONFH 39 (57,35%) 23 (51,11%) 16 (69,56%)
Smoking 27 (39,7%) 21 (46,66%) 6 (26,06%)
Diabetes mellitus 8 (11,76%) 4 (8,88%) 4 (17,39%)
Coronary disease 3 (4,41%) 2 (4,44%) 1 (4,34%)
Thrombosis 1 (1,47%) 0 1 (4,34%)
Leriche syndrome 1 (1,47%) 1 (2,22%) 0
Hypertension 13 (19,11%) 8 (17,77%) 5 (21,73%)
Hyperlipidemia 1 (1,47%) 1 (2,22%) 0
Table 4 Genotype frequencies of four polymorphisms
in ONFH patients (total, idiopathic and secondary)
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(unilateral or bilateral ONFH) (Tables 9 and 10). The
genotype and allele frequencies did not differ for Factor V
Leiden, prothrombin and MTHFR gene polymorphisms
for patients with ONFH in comparison to controls. We
have found a statistically significant increased frequency
of D allele of PLAT TPA 25 I/D polymorphism between
the entire group of patients with ONFH and controls
(p=0,026, OR=1,54 ,CI 0,99-2,4) (Table 3). D allele fre-
quency was also significantly increased in patients with
primary ONFH (p=0,009, OR=1,81 CI 1,1-3,01) (Table 3),
in males (p= 0,013; OR 1,74; 95% CIs 1,08-2,78) (Table 5),
patients older than 50 years (p= 0,018, OR= 2,04; 95% CIs
1,09-3,82) (Table 7) and in cases with bilateral ONFH
(p= 0,01; OR= 1,92; 95% CIs 1,13-3,27) (Table 9). The
differences in DD homozygous genotype frequency wereTable 3 Allele frequencies of four polymorphisms in












A 0,03 0,0225 0,0333 0
G 0,97 0,9775 0,9667 1,0
Prothrombin
A 0,01 0,0074 0 0,0218
G 0,99 0,9926 1,0 0,9782
MTHFR
T 0,28 0,3161 0,3444 0,2608
C 0,72 0,6839 0,6556 0,7392
TPA
D 0,365 0,4705a 0,5111b 0,3478
I 0,6350 0,5295 0,4889 0,6522
ap =0,026; odds ratio (OR) 1,54; 95% confidence intervals (CIs) 0,99-2,4.
bp=0,009; OR 1,81; 95% CIs 1,1-3,01.statistically significant for patients with idiopathic ONFH
compared with control group (p=0,023, OR=2,75, CI 0,99-
7,9) (Table 4) and in cases of bilateral ONFH (p=0,034; OR
3,12; 95% CIs 1,06-9,18) (Table 10). The frequencies of ID
heterozygous genotype were statistically significantly higher
in entire group of patients with ONFH (p=0,004 OR 2,71;
95% CIs 1,32-5,57) (Table 4), idiopathic ONFH (p= 0,01;
OR 2,91; 95% CIs 1,24-6,87) (Table 4), males (p=0,0007; OR
3,75; 95% CIs 1,67-8,42) (Table 6), patients older than 50
years (p=0,001; OR 6,89; 95% CIs 1,87-25,84) (Table 8) and
in cases with bilateral ONFH (p=0,009; OR 3,19; 95% CIs











GA 3(3%) 3(4,41%) 3(6,67%) 0
GG 97(97%) 65(95,59%) 42(93,33%) 23(100%)
Prothrombin
GA 2(2%) 1(1,47%) 0 1(4,35%)
GG 98(98%) 67(98,53%) 45(100%) 22(95,65%)
MTHFR
TT 7(7%) 4(5,88%) 4(8,89%) 0
CT 42(42%) 35(51,47%) 23(51,11%) 12(52,17%)
CC 51(51%) 29(42,65%) 18(40%) 11(47,83%)
TPA
DD 18(18%) 13(19,12%) 11(24,44%)a 2(8,7%)
ID 37(37%) 38(55,88%)b 24(53,33%)c 14(60,87%)
II 45(45%) 17(25%) 10(22,22%) 7(30,43%)
a p=0,023; odds ratio (OR) 2,75; 95% confidence intervals (CIs) 0,99-7,95.
bp=0,004 OR 2,71; 95% CIs 1,32-5,57.
cp= 0,01; OR 2,91; 95% CIs 1,24-6,87.
Table 5 Allele frequencies of four polymorphisms in












A 0,03 0,0225 0 0,0267
G 0,97 0,9775 1,0 0,9733
Prothrombin
A 0,01 0,0074 0 0,0089
G 0,99 0,9926 1,0 0,9911
MTHFR
T 0,28 0,3161 0,4583 0,2857
C 0,72 0,6839 0,5417 0,7143
TPA
D 0,365 0,4705a 0,3636 0,5b
I 0,6350 0,5295 0,6364 0,5
ap =0,026; odds ratio (OR) 1,54; 95% confidence intervals (CIs) 0,99-2,4.
bp= 0,013; OR 1,74; 95% CIs 1,08-2,78.
Table 7 Allele frequencies of four polymorphisms in





Total N=136 <50 n=86 >50 n=50
Factor V Leiden
A 0,03 0,0225 0,0117 0,041
G 0,97 0,9775 0,9883 0,959
Prothrombin
A 0,01 0,0074 0,0117 0
G 0,99 0,9926 0,9883 1,0
MTHFR
T 0,28 0,3161 0,267 0,38
C 0,72 0,6839 0,733 0,62
TPA
D 0,365 0,4705a 0,4302 0,54b
I 0,6350 0,5295 0,5698 0,46
ap =0,026; odds ratio (OR) 1,54; 95% confidence intervals (CIs) 0,99-2,4.
bp= 0,018, OR= 2,04; 95% CIs 1,09-3,82.
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Factor V Leiden is a protein which accelerates prothrombin
activation and thrombin generation. Factor V is inactivated
by activated protein C (APC) by proteolysis. APC serves as
a balancing anticoagulant mechanism. The G1691A point
mutation in the factor V gene alerts the first cleavage siteTable 6 Genotype frequencies of four polymorphisms
in ONFH patients in the relation to gender (total, female











GA 3(3%) 3(4,41%) 0 3(5,66%)
GG 97(97%) 65(95,59%) 12(100%) 53(94,34%)
Prothrombin
GA 2(2%) 1(1,47%) 0 1(1,78%)
GG 98(98%) 67(98,53%) 12(100%) 55(98,22%)
MTHFR
TT 7(7%) 4(5,88%) 2(18,66%) 2(3,57%)
CT 42(42%) 35(51,47%) 7(56,34%) 28(50,01%)
CC 51(51%) 29(42,65%) 3(25%) 26(46,42%)
TPA
DD 18(18%) 13(19,12%) 2(16,66%) 11(19,64%)
ID 37(37%) 38(55,88%)a 4(33,34%) 34(60,72%)b
II 45(45%) 17(25%) 6(50,0%) 11(19,64%)
ap=0,004; odds ratio(OR ) 2,71; 95% confidence intervals (CIs) 1,32-5,57.
bp=0,0007; OR 3,75; 95% CIs 1,67-8,42.involved in the inactivation of factor V by APC. Mutated
factor is less efficiently degraded by APC (APC resistance)
which leads to thrombophilia [16]. Factor V Leiden consti-
tutes the most frequent cause of inherited thrombophilia.
The mean prevalence of the mutation in healthy Caucasians
is from 4 to 5% [17]. Factor V Leiden has been established
as an important and unequivocal risk factor for venousTable 8 Genotype frequencies of four polymorphisms in





Total N=68 <50 n=43 >50 n=25
Factor V Leiden
GA 3(3%) 3(4,41%) 3(6,67%) 0
GG 97(97%) 65(95,59%) 40(93,33%) 25(100%)
Prothrombin
GA 2(2%) 1(1,47%) 1 (2,38%) 0
GG 98(98%) 67(98,53%) 42(97,62%) 25(100%)
MTHFR
TT 7(7%) 4(5,88%) 1(2,32%) 3(12%)
CT 42(42%) 35(51,47%) 22(51,16%) 13(52%)
CC 51(51%) 29(42,65%) 20(46.52%) 9(36%)
TPA
DD 18(18%) 13(19,12%) 8(18,6%) 5(20%)
ID 37(37%) 38(55,88%)a 21(48.83%) 17(68%)b
II 45(45%) 17(25%) 14(32,57%) 3(12%)
ap=0,004; odds ratio(OR ) 2,71; 95% confidence intervals (CIs) 1,32-5,57.
bp=0,001; OR 6,89; 95% CIs 1,87-25,84.
Table 9 Allele frequencies of four polymorphisms in
ONFH patients in the relation to number of affected











A 0,03 0,0225 0,0334 0,0128
G 0,97 0,9775 0,9656 0,9872
Prothrombin
A 0,01 0,0074 0,0175 0
G 0,99 0,9926 0,9825 1,0
MTHFR
T 0,28 0,3161 0,3103 0,3205
C 0,72 0,6839 0,6897 0,6795
TPA
D 0,365 0,4705a 0,3965 0,5256b
I 0,6350 0,5295 0,6035 0,4744
ap =0,026; odds ratio (OR) 1,54; 95% confidence intervals (CIs) 0,99-2,4.
bp= 0,01; OR= 1,92; 95% CIs 1,13-3,27.
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ism showed the presence of the mutation in approxi-
mately 20% of cases and an associated risk increased
fivefold [12].
Glueck et al. [6] reported a 2,8% frequency of factor V
Leiden mutation in group of patients with ONFH. ZalavrasTable 10 Genotype frequencies of four polymorphisms in
ONFH patients in the relation to number of affected











GA 3(3%) 3(4,41%) 2(6,89%) 1(2,56%)
GG 97(97%) 65(95,59%) 27(93,11%) 38(97,44%)
Prothrombin
GA 2(2%) 1(1,47%) 1(3,44%) 0
GG 98(98%) 67(98,53%) 28(96,56%) 39(100%)
MTHFR
TT 7(7%) 4(5,88%) 2(6,89%) 2(5,12%)
CT 42(42%) 35(51,47%) 14(48,27%) 21(53,84%)
CC 51(51%) 29(42,65%) 13(44,84%) 16(41,04%)
TPA
DD 18(18%) 13(19,12%) 3(10,34%) 10(25,64%)a
ID 37(37%) 38(55,88%)b 17(58,62%) 21(53,84%)c
II 45(45%) 17(25%) 9(31,04%) 8(20,52%)
ap=0,034; odds ratio (OR) 3,12; 95% confidence intervals (CIs) 1,06-9,18.
bp=0,004; OR 2,71; 95% CIs 1,32-5,57.
cp=0,009; OR 3,19; 95% CIs 1,26-8,03.et al. [18] reported a high frequency of the mutation of
factor V Leiden among patients with ON of the femoral
head (18%) in comparison to reference group (4,6%). The
prevalence of mutations was significantly increased
both in primary and secondary ON patients. The authors
emphasized that the patients and control group were
Caucasians from the same geographic area, thus eliminating
ethnicity as confounding factors in the prevalence of the
mutations. Björkman et al. [19] reported a high frequency
of factor V Leiden and prothrombin gene mutations
among patients with ONFH (17%) in comparison with the
control group of (13%). Gene mutations were significantly
higher in patients with idiopathic ONFH (29%) than
the control or secondary ONFH group. The study was
performed in southern Sweden where the prevalence of
factor V Leiden mutation is one of the highest in the world
with the frequency of 10%. Chang et al. [20] observed
neither factor V Leiden, nor prothrombin gene mutations
both in patients with ON of the femoral head and reference
group. We also have not revealed both an increased Factor
V Leiden and prothrombin gene polymorphism in patients
with ONFH.
Prothrombin is a precursor of thrombin. The G20210A
prothrombin gene mutation causes higher levels of pro-
thrombin which leads to increased generation of thrombin
and thrombophilia [13]. Prothrombin gene mutation is
present in 1 to 5% of Caucasians and is associated with
venous thrombosis [21]. None of the previous reports
have confirmed independent and significant association of
prothrombin gene mutation with ON of the femoral head
[6,20]. Zalavras et al. [18] reported higher incidence of
prothrombin gene mutation in idiopathic ON in compari-
son to reference group (8,7% versus 2,6%).
Hyperhomocysteinemia has been identified as an in-
dependent risk factor for thromboembolic diseases
[22]. Homocysteine causes damage of vascular endo-
thelial cells, propagates vascular smooth cells and
enhances coagulation activity on vascular walls [23].
5,10-methylenetetrahydrofolate reductase (MTHFR) is an
enzyme that plays a role in remethylation of homocysteine.
The C677T (alanine to valine) polymorphism in MTHFR
is reported to be involved in elevated plasma total homo-
cysteine level [24]. Glueck et al. [6] reported a statistically
significant relationship between the incidence of ONFH
and MTHFR C677T polymorphism and plasma total
homocysteine levels in a group of 36 patients. Zalavras
et al. [25] reported on statistically significantly higher
677TT homozygous genotype in 66 patients with ON
of the femoral head than in the reference group. The
incidence of 677TT homozygous genotype was more
statistically significant in patients with primary osteonecro-
sis. Asano et al. [26] reported a lack of relationship between
MTHFR C677T polymorphism in 31 Japanese patients
with secondary ON of the femoral head after renal
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polymorphism plays a role in pathogenesis of ON of
the femoral head in the Korean population. In contrast
Kim et al. [27] reported on MTHFR C677T polymorphism
in 443 patients with ONFH and 273 reference group. The
authors have not found any relationship between MTHFR
polymorphism and the incidence of ONFH both in
primary and secondary ON in Korean patients.
The results from our study do not support the data
reported by Glueck et al. [6] and Zalvaras et al. [25]
concluding that statistically significant relationship between
ONFH and MTHFR C677T polymorphism is related to
Caucasian subjects. Results similar to our study were
presented by Séguin et al. [28] and Mehsen et al. [29]
reporting on lack of correlation between the incidence of
ONFH and MTHFR C677T polymorphism in Caucasian
patients.
Tissue-type plasminogen activator is a major component
of fibrinolytic system which converts plasminogen to the
active enzyme plasmin in the presence of fibrin. Plasmin in
turn, digests the fibrin clot, forming soluble fibrin degener-
ation products. Analysis of the TPA gene has revealed a
common Alu insertion/deletion (I/D) polymorphism in
intron 8 [30]. Jern et al. [31] have demonstrated that there
is a strong correlation between genotype and in vivo
release rate of TPA. Subjects with the DD phenotype were
found to have significantly lower unstimulated release
of TPA. All 3 genotypes showed a proportional increase
in response to stimulation but the DD group showed
the lowest net release. The hypothesis that TPA Alu I/D
genotype may be associated with arterial or venous
thromboembolism has been evaluated in several clinical
studies with mixed results [32,33]. The TPA gene poly-
morphism was found to be related with increased myocar-
dial infarction among Dutch patients [34]. The II genotype
was associated with 2-fold increase of myocardial infarction
compared with DD genotype. These findings have not been
confirmed by other studies. Hooper et al. [35] reported on
a significant increase in the frequency of the DD genotype
in Afro American patients with venous thromboembolism
compared with controls. To the best of our knowledge the
correlation between TPA polymorphisms and ONFH
has not been studied previously. In our study we revealed
the significantly increased frequency of D allele and DD
homozygosis in the group of patients with idiopathic
ONFH in comparison with control group. DD genotype is
associated with decreased release of TPA, thus on the
basis of our results we conclude that TPA polymorphism
is a risk factor of ONFH in Polish patients. We have also
found the higher incidence of D allele and DD genotype
in cases bilateral ONFH, thus it may be a reason for more
severe course of the disease. The frequencies of D allele
and ID heterozygous were statistically increased in males
and patients older than 50 years and in bilateral ONFH.The relationship between PAI-1 polymorphism and ONFH
has been evaluated in other studies. Glueck et al. [36]
reported on higher incidence of 4G homozygosity of PAI-1
polymorphism in patients with ONFH (41%) in compari-
son with control subjects (20%). 61% of patients had higher
plasminogen activator inhibitor activity versus reference
group (5%). The authors concluded that heritable hypo-
fibrinolysis may be a major etiologic factor of primary
ONFH. These results were confirmed later by Glueck
et al. [6] in another group of patients with ONFH. These
results were later confirmed by Kim et al. [37] who found
significant association between PAI-1 polymorphisms and
ONFH.
Conclusions
In conclusion, our results suggest that etiology of ONFH
may be associated with abnormalities of hypofibrinolysis.
We have not found any evidence that thrombophilia
may be a risk factor of ONFH among Polish patients.
Our results demonstrate the influence of ethnicity in
differences of genetic risk factors of ONFH. Further
studies with larger size samples and more detailed
exploration of hypofibrinolysis markers are needed to
support present findings.
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